Effect of replenishment of vitamin D on survival in patients with decompensated liver cirrhosis: A prospective study.

Ashish Kumar Jha, Sharad Kumar Jha, Amarendra Kumar, Vishwa Mohan Dayal, Sanjeev Kumar Jha
{"title":"Effect of replenishment of vitamin D on survival in patients with decompensated liver cirrhosis: A prospective study.","authors":"Ashish Kumar Jha,&nbsp;Sharad Kumar Jha,&nbsp;Amarendra Kumar,&nbsp;Vishwa Mohan Dayal,&nbsp;Sanjeev Kumar Jha","doi":"10.4291/wjgp.v8.i3.133","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>To assess the vitamin D (VD) deficiency as a prognostic factor and effect of replenishment of VD on mortality in decompensated cirrhosis.</p><p><strong>Methods: </strong>Patients with decompensated liver cirrhosis were screened for serum VD levels. A total of 101 VD deficient patients (< 20 ng/mL) were randomly enrolled in two groups: Treatment group (<i>n</i> = 51) and control group (<i>n</i> = 50). Treatment group received VD treatment in the form of intramuscular cholecalciferol 300000 IU as loading dose and 800 IU/d oral as maintenance dose along with 1000 mg oral calcium supplementation. The VD level, clinical parameters and survival of both the groups were compared for 6-mo.</p><p><strong>Results: </strong>Prevalence of vitamin D deficiency (VDD) in decompensated CLD was 84.31%. The mean (SD) age of the patients in the treatment group (M:F: 40:11) and control group (M:F: 37:13) were 46.2 (± 14.93) years and 43.28 (± 12.53) years, respectively. Baseline mean (CI) VD (ng/mL) in control group and treatment group were 9.15 (8.35-9.94) and 9.65 (8.63-10.7), respectively. Mean (CI) serum VD level (ng/mL) at 6-mo in control group and treatment group were 9.02 (6.88-11.17) and 29 (23-35), respectively. Over the period of time the VD, calcium and phosphorus level was improved in treatment group compared to control group. There was non-significant trend seen in greater survival (69% <i>vs</i> 64%; <i>P</i> > 0.05) and longer survival (155 d <i>vs</i> 141 d; <i>P</i> > 0.05) in treatment group compared to control group. VD level had no significant association with mortality (<i>P</i> > 0.05). In multivariate analysis, treatment with VD supplement was found significantly (<i>P</i> < 0.05; adjusted hazard ratio: 0.48) associated with survival of the patients over 6-mo.</p><p><strong>Conclusion: </strong>VD deficiency is very common in patients of decompensated CLD. Replenishment of VD may improve survival in patients with decompensated liver cirrhosis.</p>","PeriodicalId":23760,"journal":{"name":"World Journal of Gastrointestinal Pathophysiology","volume":"8 3","pages":"133-141"},"PeriodicalIF":0.0000,"publicationDate":"2017-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4291/wjgp.v8.i3.133","citationCount":"15","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Journal of Gastrointestinal Pathophysiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4291/wjgp.v8.i3.133","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 15

Abstract

Aim: To assess the vitamin D (VD) deficiency as a prognostic factor and effect of replenishment of VD on mortality in decompensated cirrhosis.

Methods: Patients with decompensated liver cirrhosis were screened for serum VD levels. A total of 101 VD deficient patients (< 20 ng/mL) were randomly enrolled in two groups: Treatment group (n = 51) and control group (n = 50). Treatment group received VD treatment in the form of intramuscular cholecalciferol 300000 IU as loading dose and 800 IU/d oral as maintenance dose along with 1000 mg oral calcium supplementation. The VD level, clinical parameters and survival of both the groups were compared for 6-mo.

Results: Prevalence of vitamin D deficiency (VDD) in decompensated CLD was 84.31%. The mean (SD) age of the patients in the treatment group (M:F: 40:11) and control group (M:F: 37:13) were 46.2 (± 14.93) years and 43.28 (± 12.53) years, respectively. Baseline mean (CI) VD (ng/mL) in control group and treatment group were 9.15 (8.35-9.94) and 9.65 (8.63-10.7), respectively. Mean (CI) serum VD level (ng/mL) at 6-mo in control group and treatment group were 9.02 (6.88-11.17) and 29 (23-35), respectively. Over the period of time the VD, calcium and phosphorus level was improved in treatment group compared to control group. There was non-significant trend seen in greater survival (69% vs 64%; P > 0.05) and longer survival (155 d vs 141 d; P > 0.05) in treatment group compared to control group. VD level had no significant association with mortality (P > 0.05). In multivariate analysis, treatment with VD supplement was found significantly (P < 0.05; adjusted hazard ratio: 0.48) associated with survival of the patients over 6-mo.

Conclusion: VD deficiency is very common in patients of decompensated CLD. Replenishment of VD may improve survival in patients with decompensated liver cirrhosis.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
补充维生素D对失代偿肝硬化患者生存的影响:一项前瞻性研究。
目的:探讨维生素D (VD)缺乏对失代偿期肝硬化患者预后的影响及补充VD对死亡率的影响。方法:对失代偿期肝硬化患者进行血清VD水平筛查。101例VD缺陷患者(< 20 ng/mL)随机分为两组:治疗组(51例)和对照组(50例)。治疗组以肌肉注射胆骨化醇300000 IU作为负荷剂量,800iu /d作为维持剂量,同时口服补钙1000 mg。比较两组患者6个月的VD水平、临床参数及生存率。结果:失代偿期冠心病患者维生素D缺乏症(VDD)患病率为84.31%。治疗组(M:F: 40:11)和对照组(M:F: 37:13)患者的平均(SD)年龄分别为46.2(±14.93)岁和43.28(±12.53)岁。对照组和治疗组的基线平均(CI) VD (ng/mL)分别为9.15(8.35 ~ 9.94)和9.65(8.63 ~ 10.7)。对照组和治疗组6月龄血清VD水平(ng/mL)均值CI分别为9.02(6.88 ~ 11.17)和29(23 ~ 35)。随着时间的推移,治疗组的VD、钙、磷水平较对照组有所改善。生存率提高的趋势不显著(69% vs 64%;P > 0.05)和更长的生存期(155 d vs 141 d;P > 0.05)。VD水平与死亡率无显著相关性(P > 0.05)。在多因素分析中,VD补充治疗显著(P < 0.05;校正风险比:0.48)与患者超过6个月的生存率相关。结论:VD缺乏在失代偿性CLD患者中很常见。补充VD可提高失代偿期肝硬化患者的生存率。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Metabolic dysfunction-associated steatotic liver disease heterogeneity: Need of subtyping Sepsis during short bowel syndrome hospitalizations: Identifying trends, disparities, and clinical outcomes in the United States Des-gamma-carboxy prothrombin and alpha-fetoprotein levels as biomarkers for hepatocellular carcinoma and their correlation with radiological characteristics Changes in the terminology and diagnostic criteria of non-alcoholic fatty liver disease: Implications and opportunities Prevalence and outcome of sarcopenia in non-alcoholic fatty liver disease
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1